Seebri® / Ultibro® Breezhaler® 2016 sales reach $512 million triggering $5 million milestone receipt
January 25, 2017 at 9:00 AM
Chippenham, UK – 25 January 2017: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, announces that a sales milestone receipt of $5 million has been triggered following confirmation by Novartis that EU/ROW combined net sales of Seebri® Breezhaler® and Ultibro® Breezhaler® for the year to 31 December 2016 have reached $512 million. The milestone will be recorded in the Group’s revenues for 2016, as anticipated at the time of the Group’s pre-close trading update on 9 January 2017.
ノバ発表数字は略。
James Ward-Lilley, Chief Executive Officer, commented:
***
>>1046
ロイヤルティ以外に、VECTURAと同じ条件で販売額マイルがほんまに入るなら素直に嬉しい。
ほんまの楽しみは他のところにあるけどな。
Seebri® / Ultibro® Breezhaler® 2016 sales reach $512 million triggering $5 million milestone receipt
January 25, 2017 at 9:00 AM
Chippenham, UK – 25 January 2017: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, announces that a sales milestone receipt of $5 million has been triggered following confirmation by Novartis that EU/ROW combined net sales of Seebri® Breezhaler® and Ultibro® Breezhaler® for the year to 31 December 2016 have reached $512 million. The milestone will be recorded in the Group’s revenues for 2016, as anticipated at the time of the Group’s pre-close trading update on 9 January 2017.
ノバ発表数字は略。
James Ward-Lilley, Chief Executive Officer, commented: